A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Lemborexant (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 06 Jun 2017 Planned End Date changed from 30 Sep 2017 to 1 Mar 2018.
- 06 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
- 12 Nov 2016 New trial record